Give now!

Department of Infectious Diseases

Ted Ross

PhD
Professor, GRA Eminent Scholar of Infectious Disease
Director, Center for Vaccines and Immunology
Email: .(JavaScript must be enabled to view this email address)


Educational Background

  • PhD (1996) Microbiology & Immunology, Vanderbilt University
  • MS (1989) Microbiology, University of Arkansas
  • BS (1986) Zoology, University of Arkansas

About Ted Ross

Ted M. Ross is the first director of the University of Georgia’s Center for Vaccines and Immunology. Dr. Ross is a scientist with experience in the fields of virology, vaccines, immunology and microbiology. His research focuses on designing, developing and testing vaccines for viral diseases that are often at the interface of zoonotic and human interface, such as influenza, dengue, chikungunya, respiratory syncytial virus and HIV. Dr. Ross’ laboratory developed computationally-optimized broadly reactive antigen (COBRA) technology for the universal, rational design of vaccine candidates for influenza viruses. He and his laboratory has developed DNA, recombinant protein and virus-like particle (VLP) vaccines for pandemic and seasonal influenza pre-clinical and clinical research trials. Dr. Ross has multiple high impact publications in pre-clinical vaccine assessment in mice, ferrets, non-human primates, as well as human trials. He is the primary investigator on externally funded research projects. He is conducting his research with external funding from a variety of federal agencies, foundations and corporate sponsors. In 2013, Sanofi Pasteur licensed the COBRA HA vaccine technology for its Broadly-Reactive Influenza Vaccine Development Program.

Dr. Ross did his undergraduate and graduate studies in zoology and microbiology at the University of Arkansas from 1982 to 1989. He received his doctorate from Vanderbilt University in 1996 and was awarded the inaugural Sidney P. Colowick Award in Outstanding Graduate Research. Dr. Ross performed a post-doctoral fellowship at Duke University on HIV biology of viral entry and at Emory University on vaccine development for HIV and influenza viruses. He then started his own laboratory as principal investigator at East Carolina University and in 2003 moved the laboratory to the University of Pittsburgh, where he was based in the Departments of Medicine-Infectious Diseases, Microbiology and Molecular Genetics, and was a founding member of the Center for Vaccine Research for 10 years. After he left Pittsburgh, Dr. Ross served two years as the director of Vaccines and Viral Immunity at the Vaccine and Gene Therapy Institute of Florida.

Dr. Ross has published more than 130 peer-reviewed papers and book chapters on infectious disease and vaccine development. He has been an invited speaker at more than 100 national and international conferences and participates in several vaccine working groups, including at the NIH, the U.S. Centers for Disease Control and Prevention, and the World Health Organization. He is an editorial board member of Vaccine, and previously served as Editor-in-Chief of the journal Current HIV Research. In addition, he has been an ad-hoc reviewer on NIH study sections and a reviewer for 14 different journals. He served as the treasurer of the International Society for Vaccines from 2012 to 2015 and in 2015 was elected secretary. In addition, he served as the co-chair of the 8th and 9th Vaccine and ISV Congress in Philadelphia (8th) and Seoul (9th).


Research Interests

  • Development of Broadly Reactive Vaccines using computationally optimized broadly reactive antigen (COBRA) modeling. Influenza, HIV, Dengue.
  • Modeling Immunity to Biodefense agents and influenza.
  • Influenza VLP-based vaccines for seasonal and pandemic influenza.
  • Pathogenicity/Genomic Modeling of influenza infection in adult and elderly ferrets, and humans.
  • Evaluation of human clinical samples following influenza vaccination.
  • Development of tetravalent Dengue VLP-based vaccines.
  • Development of VLPs for RVFV and CCHFV.
  • Multiclade Consensus Env VLP AIDS vaccine.
  • Using Consensus Env Sequences to broaden immunity.
  • Using C3d adjuvants in a DNA vaccine to enhance the immunogenicity to HIV/SIV, RVFV, Dengue, West Nile, Chikungunya virus envelopes.
  • Development and testing pandemic H5N1, H1N1, H7N9 subtypes.

Awards

  • 1989: Gradaute Student Reseach Award, University of Arkansas
  • 1993-1995: National Research Service Award, Vanderbilt University, School of Medicine
  • 1996: Sidney P. Colowick Award for Outstanding Graduate Student Achievement, Vanderbilt University, School of Medicine
  • 2003: Appreciation of Outstanding Medical Student Teaching, East Carolina University, School of Medicine
  • 2008: Pittsburgh Life Sciences Greenhouse Award
  • 2013: Fellow-International Society for Vaccines

Selected Publications

Search PubMed for Ross TM

  • Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cort├ęs-Garcia G, Vogel TU, Parrington M, Kleanthous H, Ross TM. Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses. 2016. J Virol. 90(9). 4720-34.
  • Kirchenbaum GA, Carter DM, Ross TM. Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies. J Virol. 2015. 90(2):1116-28.
  • Carter DM, Bloom CE, Nascimento EJ, Marques ETA, Craigo JK, Cherry JL, Lipman DJ, Ross TM. Sequential Ferret H1N1 influenza infection in ferrets elicits neutralizing antibodies to emerging H1N1 isolates. 2013. J Virol. 87(2). 1400-1410.
  • Giles BM, Crevar CJ, Carter DM, Bissel SM, Schultz-Cherry S, Khurana S, Golding H, Wiley CA, and Ross TM. Computationally-Optimized Hemagglutinin Expressed on a Virus-like Particle Vaccine Elicits Broadly-Reactive Antibodies that Protect Non-human Primates from H5N1 clade 2 Influenza Infection. 2012. J. Inf. Dis. 205:1562-70.
  • Giles BM and Ross TM. Development of a computationally optimized broadly reactive (COBRA) hemagglutinin for elicitation of protective antibodies against multiple clades of H5N1. 2011. Vaccine. 29:3043-54.
  • Giles BM, Bissel SJ, DeAlmeida DR, Wiley CA, Tumpey TM, and Ross TM. A 1918 influenza virus-like particle elicits long-lasting protective immune responses to 2009 pandemic H1N1 virus. 2011. J. Virol. 86:1500-1513.
  • Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 2008. 26:5393-5393.
  • Bhardwaj N, Heise MT, Ross TM. DNA and alphavirus replicon vaccines encoding Gn elicit protective immune response against lethal Rift Valley Fever virus infection. 2009. PLoS NTD.
  • Green TD, Montefiori DC, Ross TM. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol. 2003. 77:2046-2055

Be part of the CVM Team. Give today! Ok, let's do it!